Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05199272 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
A Phase 1 study of Solid Tumor and Fallopian Tube Cancer, sponsored by 23andMe.
- Active
- Registry status
- Phase 1
- Development phase
- 141
- Enrollment target
- 13
- Study locations
NCT05199272: Active Phase 1 study of Solid Tumor and Fallopian Tube Cancer, sponsored by 23andMe.
NCT05199272 is a Phase 1 study of Solid Tumor and Fallopian Tube Cancer that is active but no longer recruiting, run by 23andMe. The registered enrollment target is 141 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (36% lower). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05199272, a Phase 1 study of Solid Tumor and Fallopian Tube Cancer, is active but no longer recruiting, sponsored by 23andMe.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 141 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard therapies
Conditions Studied
Interventions
- DRUG 23ME-00610
Study Locations (13)
Ontario
- Ottawa Hospital Cancer Centre - Ottawa
- Princess Margaret Cancer Centre - Toronto
- The Hospital for Sick Children - Toronto
New York
- R.J.Zuckerberg Cancer Center - Lake Success
- Cohen Children's Medical Center - New Hyde Park
Texas
- MD Anderson Cancer Center - Houston
- START Center for Cancer Care - San Antonio
California
- Stanford Cancer Institute - Palo Alto
Georgia
- Emory University - Atlanta
Michigan
- Karmanos Cancer Institute - Detroit
Oregon
- Oregon Health & Science University - Portland
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2021-12-29 |
| Est. Completion | 2025-03 |
| Phase | Phase 1 |
What the registry record for NCT05199272 still lists
NCT05199272 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (36% lower).
The record links to 9 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which 23ME-00610 is the first listed.
NCT05199272 lists 13 locations in 9 states (Ontario, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT05199272 about?
NCT05199272 is a clinical study titled "A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies". This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard ther...
What is the current status of trial NCT05199272?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 141 participants. The study started on 2021-12-29. Estimated completion is 2025-03.
What conditions does trial NCT05199272 study?
This clinical trial studies the following conditions: Solid Tumor, Fallopian Tube Cancer, Neuroendocrine Tumors, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer.
What interventions are being tested in trial NCT05199272?
The interventions under investigation include: 23ME-00610 (DRUG).
Who is sponsoring clinical trial NCT05199272?
This trial is sponsored by 23andMe, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05199272 being conducted?
This trial has 13 study locations across California, Georgia, Michigan, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05199272's enrollment target sits among peer trials
141 62nd of 196 higher than 135 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI